Anti-IgE therapy - 24/08/11
Doi : 10.1016/j.iac.2004.06.002
Jaine Brownell, MD, Thomas B. Casale, MD ⁎ 
Division of Allergy and Immunology, Department of Medicine, Creighton University School of Medicine, 601 North 30th Street Suite 5850 Omaha, NE 68131, USA
*Corresponding author
Résumé |
IgE has a central role in the initiation of allergic hypersensitivity reactions. Pioneered by the development of humanized monoclonal antibodies directed against IgE, anti-IgE therapy represents an original approach to the treatment of allergic disease and has demonstrated promise in preventing the symptoms of asthma, allergic rhinitis, and food allergy. The primary mechanism of action of anti-IgE therapy is the reduction in serum levels of IgE and FcɛRI expression on mast cells and basophils.
Le texte complet de cet article est disponible en PDF.Plan
| This article was supported in part by a grant from the Immune Tolerance Network, National Institute of Allergy and Infectious Diseases, and National Institutes of Health. |
© 2004
Elsevier Inc. Tous droits réservés.
Vol 24 - N° 4
P. 551-568 - novembre 2004 Retour au numéro
Article précédent
- Emerging Therapies for Allergic Diseases
- Susan M. MacDonald, Becky M. Vonakis
- New approaches in immunotherapy: allergen vaccination with immunostimulatory DNA
- Peter Socrates Creticos, Yi-Hsing Chen, John T. Schroeder
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?